Intratumoral Injection of an Immunostimulatory CpG, SD-101, Combined With Local Radiation for the Treatment of Recurrent or Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation

Trial Profile

Intratumoral Injection of an Immunostimulatory CpG, SD-101, Combined With Local Radiation for the Treatment of Recurrent or Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs SD 101 Dynavax (Primary)
  • Indications Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Nov 2016 Status changed from recruiting to discontinued due to slow accrual.
    • 17 Mar 2016 According to a Dynavax Technologies media release, interim results from this trial will be presented at the American Association for Cancer Research Annual Meeting 2016.
    • 09 Sep 2015 Status changed from suspended to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top